Sorrento Therapeutics, Inc. is pleased to announce the exciting results of the China phase IIa study of Abivertinib in the treatment of Patients with Relapsed/Refractor Marginal Zone Lymphoma (MZL). Abivertinib, a mutant EGFR and BTK dual inhibitor, showed promising outcomes with an impressive objective response rate (ORR) of 59.3%. This exceeds the ORR of the first approved treatment of R/R MZL, Ibrutinib.
To date, no severe bleeding, arrhythmia, or hypertension were observed in patients on Abivertinib treatment. These encouraging outcomes have led to an agreement with the NMPA, with plans to initiate a pivotal phase III registration study. With the potential for Abivertinib to be an effective treatment option for both Resistant EGFR mutant positive non-small cell lung cancer and R/R MZL, Sorrento is confident Abivertinib has great potential in the fight against cancer.
About Sorrento Therapeutics, Inc.
Sorrento is transforming the way we treat cancer, autoimmune diseases, and even the novel virus, COVID-19. Using its comprehensive immuno-oncology arsenal, made up of next-generation TKIs, G-MAB antibodies, DAR-T therapies, ADCs, and oncolytic virus technology, the biopharmaceutical company is developing treatments that are proving to be more effective than ever before.
Their commitment to improving patients’ lives does not end there — with the development of the non-opioid pain management small molecule, RTX, plus the approval of ZTlido for treating postherpetic neuralgia, and positive results from the C.L.E.A.R. Program for SEMDEXA, a non-opioid product for lumbosacral radicular pain, Sorrento is continuing to pave the way for groundbreaking and life-enhancing treatments.
Sorrento Therapeutics, Inc. is on the cusp of something big! With its innovative drug Abivertinib on the path to be a possible lifesaver for those suffering from relapsed/refractory Mantle Cell Lymphoma, they are quickly ascending in the medical spotlight. With its promising safety and efficacy profiles, Abivertinib is looking to supersede the previously approved drug Ibrutinib in providing treatment benefits.
With the company currently in voluntary proceedings under Chapter 11 in the Bankruptcy Court, the future is uncertain; but with communication with the Chinese NMPA regarding a pivotal phase III registration study for R/R MZL in full motion, the outlook remains hopeful. As they stand on the brink of a breakthrough, the company is determined to leverage the expertise of its employees, subsidiaries, affiliates, and partners to turn their revolutionary Abivertinib into a medical reality.